arrow
K

Keita Miura

Juntendo University Shizuoka Hospital
H指数:12
被引数:551

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A randomized phase III trial of concurrent chemoradiotherapy followed by durvalumab consolidation, with or without induction chemo-immunotherapy, in patients with unresectable locally advanced non-small cell lung cancer: JCOG2510 (PRIME-CRT)

不可切除的局部晚期非小细胞肺癌患者中,序贯度伐利尤单抗巩固治疗(含或不含诱导化免疫疗法)的同期放化疗随机III期试验:JCOG2510(PRIME-CRT)

2026-09-210
OAAI
Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer

晚期非小细胞肺癌免疫检查点抑制剂≥4年长期受益者的疾病动力学与实践模式

2026-07-280
PRE
Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non-Small Cell Lung Cancer: A Single-Institution Retrospective Study

多西他赛联合雷莫芦单抗对晚期非小细胞肺癌患者恶性胸腔积液和脑水肿的疗效:一项单机构回顾性研究

2026-05-010
OAAI
Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors

晚期非小细胞肺癌合并糖尿病且接受SGLT2抑制剂治疗患者的体重变化及其对预后的影响

2026-04-280
PRE
Efficacy of Osimertinib in Patients With Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations

奥希替尼对携带敏感EGFR突变且术后复发的非小细胞肺癌患者的疗效

2026-04-240
OAAI
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A

恶病质和一线全身治疗对未经治疗的晚期非小细胞肺癌的影响: NEJ050A

2024-10-011
OA
Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study

多重用药对PD-1/PD-L1抑制剂治疗老年晚期非小细胞肺癌患者预后的影响: 一项回顾性队列研究

2024-09-010
PRE
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
2024-01-015
OA
The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
2023-11-010
PRE
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

晚期非小细胞肺癌中基于铂类化疗联合程序性死亡-1阻滞后ramucirumab联合多西他赛的多中心真实数据: NEJ051 (反应性研究)

2023-05-0110
PRE
Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study

流行病学,危险因素和恶病质对患者预后的影响: 来自日本肺癌注册研究的结果

2023-03-1022
OA